Clinical trialNCT06375811Active, not recruitingPhase 3Interventional

Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp

SponsorYale UniversityEnrollment97EndometriosisInfertility

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET), live birth rates will improve in those pretreated with GnRH antagonist compared to those not pretreated with GnRH antagonist.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Emily Jungheim, MD
Northwestern University
Study Director
clinicaltrials.gov ↗
Heping Zhang, PhD
Yale University
Study Director
clinicaltrials.gov ↗
Hugh Taylor, MD
Yale University
Principal Investigator
clinicaltrials.gov ↗
Jim Segars, MD
Johns Hopkins University
Study Director
clinicaltrials.gov ↗
Nanette Santoro, MD
University of Colorado, Denver
Study DirectorKOL profile →
clinicaltrials.gov ↗
Steven Young, MD, PhD
Duke University
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Colorado Department of Obstetrics & Gynecology
Aurora, Colorado, United States
Yale School of Medicine Dept.of Ob/gyn & Reproductive Sciences
New Haven, Connecticut, United States
Northwestern University Department of Obstetrics and Gynecology
Chicago, Illinois, United States
Johns Hopkins, Division of Reproductive Science and Women'S Health Research
Baltimore, Maryland, United States
Duke Fertility
Morrisville, North Carolina, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Elagolix

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 16 Mar 2024
Primary completion: 31 Mar 2027
Completion: 31 Mar 2027
Last update posted: 5 Jun 2026
Registered enrollment: 97
Registry id: NCT06375811

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.